Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Lupin Q4 FY26 Results: Net Profit ₹1,469 Cr, Up 87.7% YoY

Lupin Ltd reported revenue from operations of ₹7,475 Cr (+31.9% YoY) and net profit of ₹1,469 Cr (+87.7% YoY) for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations7474.77167.55667.1
Other income140.7114.757.0
Total income7615.47282.25724.1
Profit before exceptional items & tax2059.31948.6895.8
Exceptional items-131.3-426.60.0
Profit before tax1928.01522.0895.8
Net profit1468.71180.5782.4
Operating margin25.3%20.9%15.6%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year+87.70%
Net profit, quarter on quarter+24.40%
Revenue, year on year+31.90%
Source

BSE results filing, NSE: LUPIN. Figures extracted from the filing.

Read the filing ↗

Lupin Ltd: key numbers

Share price
₹2,092.00
Market cap
₹95,665 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
17.3×Sector 50.4×
Promoter holding
46.85%-0.01% QoQ
FII holding
22.42%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
16:14 IST BSE
Employee Stock Options

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

17:38 IST NSE
Product Launch

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.